Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | QPCT | Q16769 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3787301 | 0.85 | EPHX2 (0.47) | ESRRGEPHX2POLBPDK1PDK2 | |
| SCHEMBL14236757 | 0.81 | POLB (0.39) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL17055297 | 0.80 | EPHX2 (0.46) | ESRRGEPHX2POLBPTGS1LMNA | |
| SCHEMBL22185075 | 0.79 | POLB (0.50) | POLBCYP2C19MMP8MAPTHIF1A | |
| SCHEMBL10169454 | 0.75 | SMN1; SMN2 (0.54) | LMNAALDH1A1TSHRKDM4EMAPT | |
| SCHEMBL3000922 | 0.75 | POLB (0.58) | ESRRGEPHX2POLBLMNASLC22A2 | |
| SCHEMBL2334349 | 0.74 | EPHX2 (0.42) | ESRRGEPHX2POLBPTGS1LMNA | |
| SCHEMBL13526144 | 0.72 | POLB (0.46) | POLBMAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL13526147 | 0.71 | DRD2 (0.46) | POLBMMP8MAPTHDAC3HDAC4 | |
| SCHEMBL14052421 | 0.70 | PTGS1 (0.47) | POLBPDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | claimed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | claimed |
| CN-107847600-B | Combination therapy of anti-CD 20 antibodies with Bcl-2 inhibitors and MDM2 inhibitors | 豪夫迈·罗氏有限公司 | 2021-09-03 | — | — | CN | disclosed |
| EP-3302549-B1 | COMBINATION THERAPY OF AN ANTI CD20 ANTIBODY WITH A BCL-2 INHIBITOR AND A MDM2 INHIBITOR | HOFFMANN LA ROCHE (CH) | 2019-07-03 | — | — | EP | disclosed |
| US-9657351-B2 | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist | HOFFMAN-LA ROCHE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160347852-A1 | Combination therapy of an anti-CD20 antibody with a Bcl-2 inhibitor and a MDM2 inhibitor | HOFFMANN-LA ROCHE INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-20150211073-A1 | MRNA-BASED GENE EXPRESSION FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST | HOFFMANN-LA ROCHE INC. | 2015-07-30 | — | — | US | disclosed |
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | ESRRG 1186/4885EPHX2 2619/4885KDR 420/4885 |
| US-20150211073-A1 | MRNA-BASED GENE EXPRESSION FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST | MDM2, TP53, TP53BP1 | ESRRG 796/4885EPHX2 4515/4885KDR 1695/4885 |
| US-20160347852-A1 | Combination therapy of an anti-CD20 antibody with a Bcl-2 inhibitor and a MDM2 inhibitor | BCL2L1, MCL1, CD22 | ESRRG 1206/4885EPHX2 3535/4885KDR 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.